248 related articles for article (PubMed ID: 27087157)
41. Bilateral vocal cord paralysis following treatment with vincristine.
Naithani R; Dolai TK; Kumar R
Indian Pediatr; 2009 Jan; 46(1):68-9. PubMed ID: 19179723
[TBL] [Abstract][Full Text] [Related]
42. Precision medicine to improve the risk and benefit of cancer care: genetic factors in vincristine-related neuropathy.
McLeod HL
JAMA; 2015 Feb; 313(8):803-4. PubMed ID: 25710656
[No Abstract] [Full Text] [Related]
43. Posaconazole-increased vincristine neurotoxicity in a child: a case report.
Eiden C; Palenzuela G; Hillaire-Buys D; Margueritte G; Cociglio M; Hansel-Esteller S; Peyriere H
J Pediatr Hematol Oncol; 2009 Apr; 31(4):292-5. PubMed ID: 19346885
[TBL] [Abstract][Full Text] [Related]
44. Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia.
Lavoie Smith EM; Li L; Hutchinson RJ; Ho R; Burnette WB; Wells E; Bridges C; Renbarger J
Cancer Nurs; 2013; 36(5):E49-60. PubMed ID: 23842524
[TBL] [Abstract][Full Text] [Related]
45. Clinical and electrophysiological studies in vincristine induced neuropathy.
Pal PK
Electromyogr Clin Neurophysiol; 1999 Sep; 39(6):323-30. PubMed ID: 10499201
[TBL] [Abstract][Full Text] [Related]
46. A Metabolomics Approach for Early Prediction of Vincristine-Induced Peripheral Neuropathy.
Verma P; Devaraj J; Skiles JL; Sajdyk T; Ho RH; Hutchinson R; Wells E; Li L; Renbarger J; Cooper B; Ramkrishna D
Sci Rep; 2020 Jun; 10(1):9659. PubMed ID: 32541868
[TBL] [Abstract][Full Text] [Related]
47. Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine.
Hartman A; van den Bos C; Stijnen T; Pieters R
Cancer; 2006 Mar; 106(6):1395-401. PubMed ID: 16453332
[TBL] [Abstract][Full Text] [Related]
48. Vincristine-induced vocal cord palsy: case report and review of the literature.
Latiff ZA; Kamal NA; Jahendran J; Alias H; Goh BS; Syed Zakaria SZ; Jamal R
J Pediatr Hematol Oncol; 2010 Jul; 32(5):407-10. PubMed ID: 20505534
[TBL] [Abstract][Full Text] [Related]
49. Vincristine-related neuropathy versus acute inflammatory demyelinating polyradiculoneuropathy in children with acute lymphoblastic leukemia.
Brigo F; Balter R; Marradi P; Ferlisi M; Zaccaron A; Fiaschi A; Frasson E; Bertolasi L
J Child Neurol; 2012 Jul; 27(7):867-74. PubMed ID: 22241706
[TBL] [Abstract][Full Text] [Related]
50. Vincristine induced cranial neuropathy.
Dixit G; Dhingra A; Kaushal D
J Assoc Physicians India; 2012 Mar; 60():56-8. PubMed ID: 22799120
[TBL] [Abstract][Full Text] [Related]
51. [Paralytic ileus, convulsions and hyponatremia during vincristine treatment. Observations on a case in a young girl with acute lymphocytic leukemia].
Lorini R; Larizza D; Garibaldi E; Polito E
Minerva Pediatr; 1977 Sep; 29(28):1733-8. PubMed ID: 270010
[No Abstract] [Full Text] [Related]
52. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Astigarraga I; Navajas A; Echebarria-Barona A; Garcia-Miguel P; Garcia de Andoin N; Lobo C; Guerra-Merino I; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2016 May; 17(7):731-41. PubMed ID: 27180762
[TBL] [Abstract][Full Text] [Related]
53. Pediatric Oncology Patients With Vincristine-Induced Recurrent Laryngeal Nerve Palsy: Two Case Reports and a Brief Review of Literature.
Tay SY; Foster J; Heczey A; Sitton M
Ear Nose Throat J; 2021 Dec; 100(10):NP459-NP463. PubMed ID: 32425060
[TBL] [Abstract][Full Text] [Related]
54. Vincristine neurotoxicity in the presence of hereditary neuropathy.
Trobaugh-Lotrario AD; Smith AA; Odom LF
Med Pediatr Oncol; 2003 Jan; 40(1):39-43. PubMed ID: 12426685
[No Abstract] [Full Text] [Related]
55. An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia.
Stock W; Diouf B; Crews KR; Pei D; Cheng C; Laumann K; Mandrekar SJ; Luger S; Advani A; Stone RM; Larson RA; Evans WE
Clin Pharmacol Ther; 2017 Mar; 101(3):391-395. PubMed ID: 27618250
[TBL] [Abstract][Full Text] [Related]
56. Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy.
Akbayram S; Akgun C; Doğan M; Sayin R; Caksen H; Oner AF
Indian J Pediatr; 2010 Jun; 77(6):681-3. PubMed ID: 20532679
[TBL] [Abstract][Full Text] [Related]
57. Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.
Bermúdez M; Fuster JL; Llinares E; Galera A; Gonzalez C
J Pediatr Hematol Oncol; 2005 Jul; 27(7):389-92. PubMed ID: 16012330
[TBL] [Abstract][Full Text] [Related]
58. Switching to Bortezomib may Improve Recovery From Severe Vincristine Neuropathy in Pediatric Acute Lymphoblastic Leukemia.
Joshi J; Tanner L; Gilchrist L; Bostrom B
J Pediatr Hematol Oncol; 2019 Aug; 41(6):457-462. PubMed ID: 31233464
[TBL] [Abstract][Full Text] [Related]
59. Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia.
Reinders-Messelink HA; Van Weerden TW; Fock JM; Gidding CE; Vingerhoets HM; Schoemaker MM; Göeken LN; Bökkerink JP; Kamps WA
Eur J Paediatr Neurol; 2000; 4(5):225-33. PubMed ID: 11030069
[TBL] [Abstract][Full Text] [Related]
60. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
Thomas DA; Sarris AH; Cortes J; Faderl S; O'Brien S; Giles FJ; Garcia-Manero G; Rodriguez MA; Cabanillas F; Kantarjian H
Cancer; 2006 Jan; 106(1):120-7. PubMed ID: 16331634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
